

Patient Valuation of Castration-Resistant Prostate Cancer Health States

Dawson NA, Rentz AM, Lloyd A, Matza LS, Behl AS, Mansukhani SG, Sundaram M, Macomson B, Shore N, Freedland SJ.
Disclosures: SJF, NAD, AL and NS are consultants to Janssen Scientific Affairs, LLC (JSA). ASB, MS and BM are employees of JSA and stockholders of Johnson and Johnson. Evidera is funded by JSA.

Objective


- Evaluate preferences of patients with CRPC for metastatic versus non-metastatic health states

Methods

- Utilities were derived by eliciting values for the health states in a time trade-off survey
- Participants were offered a choice between spending 5 years in the health state being rated or shorter amounts of time in full health
- 3 health states were included:
 - nmCRPC (non-metastatic CRPC)
 - mCRPC (metastatic CRPC) chemotherapy naive
 - mCRPC chemotherapy experienced

Results

- 176 participants completed the survey. Median age = 67 years



Conclusions

- Men with CRPC placed significant value on delaying metastases and avoiding treatment with chemotherapy